omega-3 fatty acids (Massachusetts General Hospital)

Omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are long-chain polyunsaturated fatty acids (PUFAs) primarily derived from fish oil. In a clinical trial led by Dr. Timothy Wilens at Massachusetts General Hospital, omega-3 supplementation was evaluated as an adjunctive therapy to stimulant medications for adults with attention deficit hyperactivity disorder (ADHD) and deficient emotional self-regulation (DESR). These lipids are thought to exert therapeutic effects by modulating cell membrane fluidity, influencing neurotransmitter systems (such as dopamine and norepinephrine), and providing anti-inflammatory properties. The MGH study specifically investigated whether high-dose EPA could alleviate emotional dysregulation symptoms that persist despite standard ADHD treatment.

Brand names

ProOmega Junior

Other names

n-3 polyunsaturated fatty acidsn3 polyunsaturated fatty acidsn 3 polyunsaturated fatty acidsfish oileicosapentaenoic aciddocosahexaenoic acidEPADHAomega-3-acid ethyl estersomega3-acid ethyl estersomega 3-acid ethyl esters